Literature DB >> 19642859

Neutrophil CD64: a diagnostic marker for infection and sepsis.

Johannes J M L Hoffmann1.   

Abstract

Neutrophilic granulocytes express Fcgamma receptor (FcgammaR) [cluster of differentiation 64 (CD64) antigen] only when they are activated. Neutrophil CD64, demonstrated using flow cytometry, can be used as a diagnostic marker of infection and sepsis. Neutrophil CD64 is superior to C-reactive protein and hematological determinations for detecting systemic infection or sepsis, since it combines high sensitivity (90% or more) with high specificity (90%-100%) in both adults and children. In addition, the test performs well in distinguishing infection from flares in autoimmune inflammatory diseases and has somewhat more limited utility for differentiating bacterial from viral infection. This review summarizes the available literature regarding CD64 as a marker of infection, and outlines future clinical studies for confirming the diagnostic performance of this promising marker.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19642859     DOI: 10.1515/CCLM.2009.224

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  44 in total

1.  Inducible Nitric Oxide Synthase in Circulating Microvesicles: Discovery, Evolution, and Evidence as a Novel Biomarker and the Probable Causative Agent for Sepsis.

Authors:  Robert J Webber; Richard M Sweet; Douglas S Webber
Journal:  J Appl Lab Med       Date:  2019-01

2.  Neutrophil CD64 Expression as a Diagnostic Marker in Patients Hospitalized with Exacerbations of COPD: A Prospective Observational Study.

Authors:  Elena Titova; Marthe Wedø Aune; Kristin Fonn; Anne Hildur Henriksen; Arne Åsberg
Journal:  Lung       Date:  2015-07-15       Impact factor: 2.584

3.  Analysis of the temperature affects on leukocyte surface antigen expression.

Authors:  Joel Jämsä; Virva Huotari; Eeva-Riitta Savolainen; Hannu Syrjälä; Tero Ala-Kokko
Journal:  J Clin Lab Anal       Date:  2011       Impact factor: 2.352

4.  A Flow Cytometric Method for Isolating Cystic Fibrosis Airway Macrophages from Expectorated Sputum.

Authors:  Katherine B Hisert; W Conrad Liles; Anne M Manicone
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

5.  Determination of neutrophil CD64 expression as a prognostic biomarker in patients with community-acquired pneumonia.

Authors:  J Burgos; I Los-Arcos; D Álvarez de la Sierra; V Falcó; A Aguiló; I Sánchez; B Almirante; M Martinez-Gallo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-30       Impact factor: 3.267

Review 6.  Biomarkers of sepsis and their potential value in diagnosis, prognosis and treatment.

Authors:  Mary Sandquist; Hector R Wong
Journal:  Expert Rev Clin Immunol       Date:  2014-08-21       Impact factor: 4.473

7.  Neutrophil CD64 expression is a predictor of mortality for patients in the intensive care unit.

Authors:  Qiqi Chen; Junfeng Shi; Aihua Fei; Feilong Wang; Shuming Pan; Weiwei Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

8.  Fcγ receptor I alpha chain (CD64) expression in macrophages is critical for the onset of meningitis by Escherichia coli K1.

Authors:  Rahul Mittal; Sunil K Sukumaran; Suresh K Selvaraj; David G Wooster; M Madan Babu; Alan D Schreiber; J Sjef Verbeek; Nemani V Prasadarao
Journal:  PLoS Pathog       Date:  2010-11-18       Impact factor: 6.823

9.  Markedly elevated CD64 expression on neutrophils and monocytes as a biomarker for diagnosis and therapy assessment in Kawasaki disease.

Authors:  Sho Hokibara; Norimoto Kobayashi; Keiko Kobayashi; Tomonari Shigemura; Haruo Nagumo; Masahiro Takizawa; Takashi Yamazaki; Kazunaga Agematsu
Journal:  Inflamm Res       Date:  2016-03-28       Impact factor: 4.575

10.  Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease.

Authors:  A Therrien; L Chapuy; M Bsat; M Rubio; G Bernard; E Arslanian; K Orlicka; A Weber; B-P Panzini; J Dorais; E-J Bernard; G Soucy; M Bouin; M Sarfati
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.